Deregulation of HOX b13 expression in urinary bladder cancer progression

L. Marra, M. Cantile, G. Scognamiglio, L. Marra, S. Perdonà, E. La Mantia, M. Cerrone, V. Gigantino, C. Cillo, M. Caraglia, S. Pignata, G. Facchini, G. Botti, S. Chieffi, P. Chieffi, R. Franco

Research output: Contribution to journalArticle

Abstract

Urinary bladder cancer is a common malignancy in industrialized countries. More than 90% of bladder cancer originates in the transitional cells. Bladder transitional cancer prognosis is, according to the most recent definition related to the level of tumor infiltration, characterized by two main phenotypes, Non Muscle Invasive Bladder Transitional Cancer (NMIBC) and Muscle Invasive Bladder Transitional Cancer (MIBC). The genetic profile and the clinical course of the two subtypes are completely different, however among NMIBC the prognosis is not completely predictable, since 20% of the cases experience a relapse, even in the form of MIBC. It has recently been reported that the chromosomal region 12q13-15, containing crucial cancer genes such as MDM2, CDK4, GLI and an entire cluster of HOX genes, is amplified in bladder cancer. HOX genes codify for transcriptionl factor, involved in embryonal development and cancer progression, with main nuclear expression. Particularly it was also described the strong involvement of HOX B13 in several tumors of urogenital system. In this study we have been investigated, by immunohistochemisty and quantitative Real Time PCR, the HOX B13 expression in bladder cancer evolution and progression, evaluating its ability to discriminate between NMIBC and MBCI phenotypes. Cytoplasmic HOX B13 delocalization significantly relates with muscle invasion (p 0.004). In addition in the series of NMIBC nuclear HOX B13 expression loss is significantly associated to shorter disease free survival (p-value=0.038) defining a potential prognostic role. Overexpression of HOX B13 in more aggressive phenotype is also demonstrate at gene level by quantitative RT-PCR. The de-regulation and delocalization of HOX B13 in urinary bladder cancer supports again the important role of HOX genes in tumor evolution and represents a starting point to establish an integrated analysis, in which HOX genes represent important prognostic and predictive markers for bladder cancer.

Original languageEnglish
Pages (from-to)833-839
Number of pages7
JournalCurrent Medicinal Chemistry
Volume20
Issue number6
Publication statusPublished - Feb 2013

Fingerprint

Deregulation
Urinary Bladder Neoplasms
Muscle
Genes
Tumors
Muscles
Phenotype
Infiltration
Neoplasms
Muscle Neoplasms
Urogenital System
Germ Cell and Embryonal Neoplasms
Neoplasm Genes
Multigene Family
Developed Countries
Disease-Free Survival
Real-Time Polymerase Chain Reaction

Keywords

  • Bladder Tcc
  • Cytoplasmic Protein Expression
  • Hox B13
  • Immunohistochemistry Analysis
  • Muscle Invasive
  • Non-Muscle Invasive
  • Nuclear Protein Expression
  • Real Time PCR
  • Transcription Factors
  • Tumor Progression

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Marra, L., Cantile, M., Scognamiglio, G., Marra, L., Perdonà, S., La Mantia, E., ... Franco, R. (2013). Deregulation of HOX b13 expression in urinary bladder cancer progression. Current Medicinal Chemistry, 20(6), 833-839.

Deregulation of HOX b13 expression in urinary bladder cancer progression. / Marra, L.; Cantile, M.; Scognamiglio, G.; Marra, L.; Perdonà, S.; La Mantia, E.; Cerrone, M.; Gigantino, V.; Cillo, C.; Caraglia, M.; Pignata, S.; Facchini, G.; Botti, G.; Chieffi, S.; Chieffi, P.; Franco, R.

In: Current Medicinal Chemistry, Vol. 20, No. 6, 02.2013, p. 833-839.

Research output: Contribution to journalArticle

Marra, L, Cantile, M, Scognamiglio, G, Marra, L, Perdonà, S, La Mantia, E, Cerrone, M, Gigantino, V, Cillo, C, Caraglia, M, Pignata, S, Facchini, G, Botti, G, Chieffi, S, Chieffi, P & Franco, R 2013, 'Deregulation of HOX b13 expression in urinary bladder cancer progression', Current Medicinal Chemistry, vol. 20, no. 6, pp. 833-839.
Marra L, Cantile M, Scognamiglio G, Marra L, Perdonà S, La Mantia E et al. Deregulation of HOX b13 expression in urinary bladder cancer progression. Current Medicinal Chemistry. 2013 Feb;20(6):833-839.
Marra, L. ; Cantile, M. ; Scognamiglio, G. ; Marra, L. ; Perdonà, S. ; La Mantia, E. ; Cerrone, M. ; Gigantino, V. ; Cillo, C. ; Caraglia, M. ; Pignata, S. ; Facchini, G. ; Botti, G. ; Chieffi, S. ; Chieffi, P. ; Franco, R. / Deregulation of HOX b13 expression in urinary bladder cancer progression. In: Current Medicinal Chemistry. 2013 ; Vol. 20, No. 6. pp. 833-839.
@article{fed1760d4e7b46c88c203d3b896a5b44,
title = "Deregulation of HOX b13 expression in urinary bladder cancer progression",
abstract = "Urinary bladder cancer is a common malignancy in industrialized countries. More than 90{\%} of bladder cancer originates in the transitional cells. Bladder transitional cancer prognosis is, according to the most recent definition related to the level of tumor infiltration, characterized by two main phenotypes, Non Muscle Invasive Bladder Transitional Cancer (NMIBC) and Muscle Invasive Bladder Transitional Cancer (MIBC). The genetic profile and the clinical course of the two subtypes are completely different, however among NMIBC the prognosis is not completely predictable, since 20{\%} of the cases experience a relapse, even in the form of MIBC. It has recently been reported that the chromosomal region 12q13-15, containing crucial cancer genes such as MDM2, CDK4, GLI and an entire cluster of HOX genes, is amplified in bladder cancer. HOX genes codify for transcriptionl factor, involved in embryonal development and cancer progression, with main nuclear expression. Particularly it was also described the strong involvement of HOX B13 in several tumors of urogenital system. In this study we have been investigated, by immunohistochemisty and quantitative Real Time PCR, the HOX B13 expression in bladder cancer evolution and progression, evaluating its ability to discriminate between NMIBC and MBCI phenotypes. Cytoplasmic HOX B13 delocalization significantly relates with muscle invasion (p 0.004). In addition in the series of NMIBC nuclear HOX B13 expression loss is significantly associated to shorter disease free survival (p-value=0.038) defining a potential prognostic role. Overexpression of HOX B13 in more aggressive phenotype is also demonstrate at gene level by quantitative RT-PCR. The de-regulation and delocalization of HOX B13 in urinary bladder cancer supports again the important role of HOX genes in tumor evolution and represents a starting point to establish an integrated analysis, in which HOX genes represent important prognostic and predictive markers for bladder cancer.",
keywords = "Bladder Tcc, Cytoplasmic Protein Expression, Hox B13, Immunohistochemistry Analysis, Muscle Invasive, Non-Muscle Invasive, Nuclear Protein Expression, Real Time PCR, Transcription Factors, Tumor Progression",
author = "L. Marra and M. Cantile and G. Scognamiglio and L. Marra and S. Perdon{\`a} and {La Mantia}, E. and M. Cerrone and V. Gigantino and C. Cillo and M. Caraglia and S. Pignata and G. Facchini and G. Botti and S. Chieffi and P. Chieffi and R. Franco",
year = "2013",
month = "2",
language = "English",
volume = "20",
pages = "833--839",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "6",

}

TY - JOUR

T1 - Deregulation of HOX b13 expression in urinary bladder cancer progression

AU - Marra, L.

AU - Cantile, M.

AU - Scognamiglio, G.

AU - Marra, L.

AU - Perdonà, S.

AU - La Mantia, E.

AU - Cerrone, M.

AU - Gigantino, V.

AU - Cillo, C.

AU - Caraglia, M.

AU - Pignata, S.

AU - Facchini, G.

AU - Botti, G.

AU - Chieffi, S.

AU - Chieffi, P.

AU - Franco, R.

PY - 2013/2

Y1 - 2013/2

N2 - Urinary bladder cancer is a common malignancy in industrialized countries. More than 90% of bladder cancer originates in the transitional cells. Bladder transitional cancer prognosis is, according to the most recent definition related to the level of tumor infiltration, characterized by two main phenotypes, Non Muscle Invasive Bladder Transitional Cancer (NMIBC) and Muscle Invasive Bladder Transitional Cancer (MIBC). The genetic profile and the clinical course of the two subtypes are completely different, however among NMIBC the prognosis is not completely predictable, since 20% of the cases experience a relapse, even in the form of MIBC. It has recently been reported that the chromosomal region 12q13-15, containing crucial cancer genes such as MDM2, CDK4, GLI and an entire cluster of HOX genes, is amplified in bladder cancer. HOX genes codify for transcriptionl factor, involved in embryonal development and cancer progression, with main nuclear expression. Particularly it was also described the strong involvement of HOX B13 in several tumors of urogenital system. In this study we have been investigated, by immunohistochemisty and quantitative Real Time PCR, the HOX B13 expression in bladder cancer evolution and progression, evaluating its ability to discriminate between NMIBC and MBCI phenotypes. Cytoplasmic HOX B13 delocalization significantly relates with muscle invasion (p 0.004). In addition in the series of NMIBC nuclear HOX B13 expression loss is significantly associated to shorter disease free survival (p-value=0.038) defining a potential prognostic role. Overexpression of HOX B13 in more aggressive phenotype is also demonstrate at gene level by quantitative RT-PCR. The de-regulation and delocalization of HOX B13 in urinary bladder cancer supports again the important role of HOX genes in tumor evolution and represents a starting point to establish an integrated analysis, in which HOX genes represent important prognostic and predictive markers for bladder cancer.

AB - Urinary bladder cancer is a common malignancy in industrialized countries. More than 90% of bladder cancer originates in the transitional cells. Bladder transitional cancer prognosis is, according to the most recent definition related to the level of tumor infiltration, characterized by two main phenotypes, Non Muscle Invasive Bladder Transitional Cancer (NMIBC) and Muscle Invasive Bladder Transitional Cancer (MIBC). The genetic profile and the clinical course of the two subtypes are completely different, however among NMIBC the prognosis is not completely predictable, since 20% of the cases experience a relapse, even in the form of MIBC. It has recently been reported that the chromosomal region 12q13-15, containing crucial cancer genes such as MDM2, CDK4, GLI and an entire cluster of HOX genes, is amplified in bladder cancer. HOX genes codify for transcriptionl factor, involved in embryonal development and cancer progression, with main nuclear expression. Particularly it was also described the strong involvement of HOX B13 in several tumors of urogenital system. In this study we have been investigated, by immunohistochemisty and quantitative Real Time PCR, the HOX B13 expression in bladder cancer evolution and progression, evaluating its ability to discriminate between NMIBC and MBCI phenotypes. Cytoplasmic HOX B13 delocalization significantly relates with muscle invasion (p 0.004). In addition in the series of NMIBC nuclear HOX B13 expression loss is significantly associated to shorter disease free survival (p-value=0.038) defining a potential prognostic role. Overexpression of HOX B13 in more aggressive phenotype is also demonstrate at gene level by quantitative RT-PCR. The de-regulation and delocalization of HOX B13 in urinary bladder cancer supports again the important role of HOX genes in tumor evolution and represents a starting point to establish an integrated analysis, in which HOX genes represent important prognostic and predictive markers for bladder cancer.

KW - Bladder Tcc

KW - Cytoplasmic Protein Expression

KW - Hox B13

KW - Immunohistochemistry Analysis

KW - Muscle Invasive

KW - Non-Muscle Invasive

KW - Nuclear Protein Expression

KW - Real Time PCR

KW - Transcription Factors

KW - Tumor Progression

UR - http://www.scopus.com/inward/record.url?scp=84877965505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877965505&partnerID=8YFLogxK

M3 - Article

C2 - 23276138

AN - SCOPUS:84877965505

VL - 20

SP - 833

EP - 839

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 6

ER -